Wes Wheeler Appointed as CEO by Marken's Board of Directors
The Marken Board of Directors is pleased to announce the appointment of Wesley P. Wheeler, MBA as Chief Executive Officer. Mr. Wheeler succeeds Gerard Barba, who willremain the Chairman of the Marken Board of Directors.
Marken’s Board and executive management team have sought to add an executive such as Mr. Wheeler for his in depth of experience in the life science industry as well as a strong background in logistics to further strengthen market leadership and maintain Marken’s growth path.
Prior to joining Marken, Wes held the title of President and CEO of Patheon Inc., a contract manufacturing services company. Wes was also a former President of Valeant Pharmaceuticals International, and has previously held senior executive roles of increasing responsibility in manufacturing, marketing and engineering at GlaxoSmithKline, plc. Preceding his 22 year career in pharmaceuticals, Mr. Wheeler had a successful 12 year career at ExxonMobil. He holds a bachelor’s degree in Mechanical Engineering and aMasters of Business Administration.
“As the nature of biopharmaceutical R&D changes, well controlled clinical supply chains will be a significant factor in the success of key life science companies and the industries that support them. The Board and I feel that Wes can bring his experience from the drug manufacturing, biotechnology, and traditional pharmaceutical industries to augment an already strong management team and continue Marken’s growth”, said Gerard Barba,Marken’s Chairman.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
